Mutant thyroid hormone receptor β represses the expression and transcriptional activity of peroxisome proliferator-activated receptor γ during thyroid carcinogenesis

Cancer Research

Volumn 63, Issue 17, 2003, Pages 5274-5280

  Ying, Hao ^a   Suzuki, Hideyo ^a   Zhao, Li ^a   Willingham, Mark C ^c   Meltzer, Paul ^b   Cheng, Sheue Yann ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; HYBRID PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR SUBTYPE; THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR BETA; TRANSCRIPTION FACTOR PAX8; TROGLITAZONE; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISASTER; DRUG TARGETING; FUSION GENE; GENE FUNCTION; GENE MUTATION; GENE PAX8; GENETIC TRANSFECTION; HYPERPLASIA; METASTASIS; MOUSE; MOUSE STRAIN; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RECEPTOR GENE; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, FOLLICULAR; ANIMALS; IMMUNOHISTOCHEMISTRY; LIPOPROTEIN LIPASE; MICE; MUTATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, THYROID HORMONE; RNA, MESSENGER; THYROID HORMONE RECEPTORS BETA; THYROID NEOPLASMS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0141705447     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gillenwater, A. M., and Weber, R. S. Thyroid carcinoma. Cancer Treat. Res., 90: 149-169, 1997.
2. Fagin, J. A. Perspective: lessons learned from molecular genetic studies of thyroid cancer: insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology, 43: 2025-2028, 2002.
3. Santoro, M., Chiappetta, G., Cerrato, A., Salvatore, D., Zhang, L., Manzo, G., Picone, A., Portella, G., Santelli, G., Vecchio, G., et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene, 12: 1821-1826, 1996.
4. Jhiang, S. M., Sagartz, J. E., Tong, Q., Parker-Thornburg, J., Capen, C. C., Cho, J. Y., Xing, S., and Ledent, C. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology, 137: 375-378, 1996.
5. Powell, D. J., Jr., Russell, J., Nibu, K., Li, G., Rhee, E., Liao, M., Goldstein, M., Keane, W. M., Santoro, M., Fusco, A., et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res., 58: 5523-5528, 1998.
6. Fagin, J. A. Brinded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol. Endocrinol., 16: 903-911, 2002.
7. Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C. J., Mueller, E., Spiegelman, B. M., and Fletcher, J. A. PAX8-PPARγ 1 fusion oncogene in human thyroid carcinoma. Science (Wash. DC), 289: 1357-1360, 2000.
8. Nikiforova, M. N., Biddinger, P. W., Caudill, C. M., Kroll, T. G., and Nikiforov, Y. E. PAX8-PPARγ rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am. J. Surg. Pathol., 26: 1016-1023, 2002.
9. Kaneshige, M., Kaneshige, K., Zhu, X. G., Dace, A., Garrett, L., Carter, T. A., Kazlauskaite, R., Pankratz, D. G., Wynshaw-Boris, A., Weintraub, B., et al. Mice with a targeted mutation in the thyroid hormone β receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc. Natl. Acad. Sci. USA, 97: 13209-13214, 2000.
10. Weiss, R. E., and Refetoff, S. Resistance to thyroid hormone. Rev. Endocr. Metab. Disord., 1: 97-108, 2000.
11. Ono, S., Schwartz, I. D., Mueller, O. T., Root, A. W., Usala, S. J., and Bercu, B. B. Homozygosity for a dominant negative thyroid hormone receptor gene responsible for generalized resistance to thyroid hormone. J. Clin. Endocrinol. Metab., 73: 990-994, 1991.
12. Parrilla, R., Mixson, A. J., McPherson, J. A., McClaskey, J. H., and Weintraub, B. D. Characterization of seven novel mutations of the c-erbA β gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain. J. Clin. Investig., 88: 2123-2130, 1991.
13. Meier, C. A., Dickstein, B. M., Ashizawa, K., McClaskey, J. H., Muchmore, P., Ransom, S. C., Merke, J. B., Hao, E. U., Usala, S. J., Bercu, B. B., et al. Variable transcriptional activity and ligand binding of mutant β1 receptors from four families with generalized resistance to thyroid hormone. Mol. Endocrinol., 6: 248-258, 1992.
14. Suzuki, H., Willingham, M. C., and Cheng, S. Y. Mice with a mutation in the thyroid hormone receptor β gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid, 12: 963-969, 2002.
15. Jeker, L. T., Hejazi, M., Burek, C. L., Rose, N. R., and Caturegli, P. Mouse thyroid primary culture. Biochem. Biophys. Res. Commun., 257: 511-515, 1999.
16. Berlingieri, M., Portella, G., Grieco, M., Santoro, M., and Fusco, A. Cooperation between the polyomavirus middle-T-antigen gene and the human c-myc oncogene in a rat thyroid epithelial differentiated cell line: model of in vitro progression. Mol. Cell. Biol., 8: 2261-2266, 1988.
17. Pasca di Magliano, M., Di Lauro, R., and Zannini, M. Pax8 has a key role in thyroid cell differentiation. Proc. Natl. Acad. Sci. USA., 97: 13144-13149, 2000.
18. Zhu, X. G., McPhie, P., Lin, K. H., and Cheng, S. Y. The differential hormone-dependent transcriptional activity of thyroid hormone receptor isoforms is mediated by interplay of their domains. J. Biol. Chem., 272: 9048-9054, 1997.
19. Levy, O., Dai, G., Riedel, C., Ginter, C. S., Paul, E. M., Lebowitz, A. N., and Carrasco, N. Characterization of the thyroid Na+/I- symporter with an anti-COOH terminus antibody. Proc. Natl. Acad. Sci. USA., 94: 5568-5573, 1997.
20. Sun, J., Li, J., Carrasco, N., and Kaback, H. R. The last two cytoplasmic loops in the lactose permease of Escherichia coli comprise a discontinuous epitope for a monoclonal antibody. Biochemistry, 36: 274-280, 1997.
21. 3 response element-dependent dominant negative potency. J. Clin. Investig., 92: 1986-1993, 1993.
22. Zhu, X-G., McPhie, P., and Cheng, S-Y. Differential sensitivity of thyroid hormone receptor isoform homodimers and mutant heterodimers to hormone-induced dissociation from DNA: its role in dominant negative action. Endocrinology, 138: 1456-1463, 1997.
23. Schoonjans, K., Peinado-Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., and Auwerx, J. PPARα and PPARγ activators direct a distinct tissuc-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J., 15: 5336-5348, 1996.
24. Goldberg, I. J., and Merkel, M. Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front Biosci., 6: D388-D405, 2001.
25. Lin, K. H., Shieh, H. Y., Chen, S. L., and Hsu, H. C. Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol. Carcinog., 26: 53-61, 1999.
26. Kamiya, Y., Puzianowska-Kuznicka, M., McPhie, P., Nauman, J., Chcng, S-Y., and Nauman, A. Expression of mutant thyroid hormone nuclear receptors associated with human renal clear cell carcinoma. Carcinogenesis (Lond.), 23: 25-33, 2002.
27. Puzianowska-Kuznicka, M., Krystyniak, A., Madej, A., Cheng, S. Y., and Nauman, J. Functionally impaired TR mutants are present in thyroid papillary cancer. J. Clin. Endocrinol. Metab., 87: 1120-1128, 2002.
28. Wong, R., Zhu, X., Pineda, M. A., Cheng, S-Y., and Weintraub, B. D. Cell type-dependent modulation of the dominant negative action of human mutant thyroid hormone β1 receptors. Mol. Med., 1: 306-319, 1995.
29. Kimura, T., Van Keymeulen, A., Golstein, J., Fusco, A., Dumont, J. E., and Roger, P. P. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro model. Endocr Rev., 22: 631-656, 2001.
30. Dumont, J. E., Dremier, S., Pirson, I., and Maenhaut, C. Cross signaling, cell specificity, and physiology. Am. J. Physiol. Cell. Physiol., 283: C2-C28, 2002.
31. Girnun, G. D., Smith, W. M., Drori, S., Sarraf, P., Mueller, E., Eng, C., Nambiar, P., Rosenberg, D. W., Bronson, R. T., Edelmann, W., et al. APC-dependent suppression of colon carcinogenesis by PPARγ. Proc. Natl. Acad. Sci. USA, 99: 13771-13776, 2002.
32. Akiyama, T. E., Nicol, C. J., and Gonzalez, F. J. On par with PPARγ. Trends Genet., 17: 310-312, 2001.
33. Martelli, M. L., luliano, R., Le Pera, I., Sama, I., Monaco, C., Cammarota, S., Kroll, T., Chiariotti, L., Santoro, M., and Fusco, A. Inhibitory effects of peroxisome proliferator-activated receptor γ on thyroid carcinoma cell growth. J. Clin. Endocrinol. Metab., 87: 4728-4735, 2002.
34. Ohta, K., Endo, T., Haraguchi, K., Hershman, J. M., and Onaya, T. Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab., 86: 2170-2177, 2001.